
Browsing restrictions can be lifted for a fee.
As of Q4'25, Pfizer's current contract liabilities have decreased to 0 USD, marking a significant reduction from the previous quarter's value of 924M USD. This latest data point reflects a complete drawdown of current contract liabilities by the end of 2025. Over the period from Q1'23 to Q4'25, the chart shows notable volatility, with liabilities peaking at 2.7B USD in Q4'23 before entering a sustained decline throughout 2024 and 2025. After reaching 2.53B USD in Q2'24, there is a consistent downward trend, culminating in a full reduction to zero by Q4'25, indicating either fulfillment or cancellation of outstanding contractual obligations.